Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd.

Company

News

Products

R&D

Investor relationship

Human Resource

Contact Us

News

	As Category 1 of Therapeutic Biological Product, “Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal” has achieved Clinical Trial Permission with approval number of 2018L02789 2018-07-20 10:30

	As Category 1 of Therapeutic Biological Product, “Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal” has achieved Clinical Trial Permission with approval number of 2018L02789。

（沪）-非经营性-2024-0273